William Blair Investment Management LLC increased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 11.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,560,247 shares of the company’s stock after purchasing an additional 159,594 shares during the period. William Blair Investment Management LLC owned approximately 0.05% of GeneDx worth $112,806,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. First Light Asset Management LLC increased its position in GeneDx by 222.7% in the 2nd quarter. First Light Asset Management LLC now owns 783,923 shares of the company’s stock valued at $53,816,000 after buying an additional 540,996 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in GeneDx by 108.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company’s stock valued at $45,723,000 after acquiring an additional 328,980 shares in the last quarter. Amova Asset Management Americas Inc. boosted its holdings in GeneDx by 67.3% during the first quarter. Amova Asset Management Americas Inc. now owns 638,800 shares of the company’s stock worth $41,024,000 after purchasing an additional 257,075 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of GeneDx by 2.0% in the 2nd quarter. Wellington Management Group LLP now owns 347,927 shares of the company’s stock worth $23,885,000 after buying an additional 6,922 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in GeneDx by 38.6% in the 1st quarter. Bank of New York Mellon Corp now owns 315,508 shares of the company’s stock valued at $20,262,000 after purchasing an additional 87,922 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other GeneDx news, CFO Kevin Feeley sold 3,728 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the completion of the transaction, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. This represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the transaction, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This trade represents a 8.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 19,206 shares of company stock valued at $1,808,056. 25.17% of the stock is owned by corporate insiders.
GeneDx Stock Performance
WGS opened at $52.37 on Monday. The business has a 50 day simple moving average of $73.83 and a two-hundred day simple moving average of $70.20. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -13.85 and a beta of 2.00. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.16 and a quick ratio of 3.85.
GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.21. The business had revenue of $123.10 million for the quarter, compared to the consensus estimate of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. During the same period in the previous year, the firm earned ($0.27) EPS. Analysts predict that GeneDx Holdings Corp. will post -0.41 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on WGS. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Guggenheim increased their target price on shares of GeneDx from $74.00 to $83.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Canaccord Genuity Group upped their price objective on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Wall Street Zen upgraded GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price (down from $90.00) on shares of GeneDx in a research note on Tuesday, November 10th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus price target of $90.14.
Get Our Latest Research Report on GeneDx
About GeneDx
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
